Value in Health: Defining a Core Data Set for the Economic Evaluation of Precision Oncology
Despite the growing abundance of multiomic data in precision oncology, the lack of standardization and interoperability impedes economic evaluation. In the latest issue of Value in Health, Samantha Pollard, PhD et al. found significant variability in published data resources. Through their work, they identified a core set of 68 data elements that they believe would support accurate and efficient economic evaluations.
Whitepaper – Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelinesv
Despite a growing understanding of cancer biology, only 10% of cancer treatments approved by the FDA have an overall survival benefit for patients. A newly available white paper lays out the current precision medicine landscape and how the shift towards adaptive trial designs could accelerate market access and improve patient outcomes
Why Don’t Oncologists Order Molecular Testing?
Many oncologists do not order molecular testing for precision oncology treatment despite the established benefits. An article in JCO Precision [...]
GeneMatters and Concert Genetics Partner to Offer Personalized Genetics Services
GeneMatters, a genetics software company, and Concert Genetics, a genetic testing management company, have announced a new partnership. Together, they [...]
Will ‘All of Us’ Bring Positive Change to Research?
“All of Us” is the $1.5 billion initiative led by the federal government with the purpose of collecting health data from [...]
Progress with Gene Therapies Requires Medicare Reform
Novel therapeutic approaches, although promising in the personalized medicine space, remain hampered by cost issues when it comes to Medicare [...]
